Obesity Drug Meridia Withdrawn from Market
The U.S. Food and Drug Administration (FDA) announced today that Abbott Laboratories has agreed to voluntarily withdraw its obesity drug Meridia (sibutramine) because scientific research has shown that the drug increases the risk of heart attack and stroke. According to John Jenkins, MD, director of the Office of New Drugs in the FDA’s Center for …